Online inquiry

IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9038MR)

This product GTTS-WQ9038MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets FLT1 gene. The antibody can be applied in Colon Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001159920.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2321
UniProt ID P17948
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9038MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14195MR IVTScrip™ mRNA-Anti-IL17A, RG4934(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RG4934
GTTS-WQ6281MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ187MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ1571MR IVTScrip™ mRNA-Anti-MSTN, ACE-083(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-083
GTTS-WQ14594MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ10273MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LFG 316
GTTS-WQ7827MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ1564MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACE-041
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW